{
  "docId": "019dd923-622b-71dc-a6da-84595e2c37a3",
  "docSlug": "08680a75fcb3",
  "documentTitle": "Pfizer Inc. (PFE)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 74,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "cite_precedent",
  "function": "cite_precedent",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Uses highlighted text within quotes to emphasize key claims.",
  "elementsJson": [
    "headline_text",
    "quote_block",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/32",
  "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "callout",
      "text": "The Company told investors GLP-1s were a $10 billion sales opportunity.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dfb1069-2bbd-4b5b-9a45-0f14d22ba260",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "sales target: $10 billion",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-e6eb-753a-a395-11e16f549333",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Excerpts from Company Transcripts",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65790123-a5de-4df3-b15b-a8775ac3a740",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "quote",
      "text": "Now we will see how things will evolve. But that's one clearly. GLP-1, clearly, everybody is excited about that. I believe that it is something that could -- we said that we think it could be $10 billion product for us in a market that could be $90 billion.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72477b9d-f656-4758-bc5f-82988be796bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "quote",
      "text": "We're happy to speak about our exciting GLP-1 programs... We believe that oral GLP-1s will take 30% of this opportunity... And that's how we get to our $10 billion global opportunity for Pfizer oral GLP-1.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "775198ad-f9da-4002-aafd-3faa28254d33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"we said that we think it could be $10 billion product for us in a market that could be $90 billion. Clearly, we are going to be one of them.\" — Albert Bourla (PFE CEO), January 9, 2023; \"And that's how we get to our $10 billion global opportunity for Pfizer oral GLP-1.\" — Andy Schmeltz (PFE Global President of Oncology), February 16, 2023",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd952-e6eb-753a-a395-0e67692f69b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Public company transcripts. Quotes are bolded and underlined for emphasis.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c52c803-0569-404c-a8f4-62bb0a8cce5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "At the Beginning of 2023, the Company Also Set a $10 Billion Sales Target for GLP-1s",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4f9ba79-1997-4298-84db-1c7ac28b5629",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "373672ac-9d47-479c-b1be-c4d6fa5d1597",
      "evidence": "Uses direct quotes from CEO and President to validate a claim.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 73,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07",
      "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.",
      "position": 0,
      "objective": "What are the costs of inaction for Pfizer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 71,
      "from": 11,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f",
      "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.",
      "position": 1,
      "objective": "How can Pfizer improve its performance?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}